Atovaquone Compared with Dapsone for the Prevention of Pneumocystis carinii Pneumonia in Patients with HIV Infection Who Cannot Tolerate Trimethoprim, Sulfonamides, or Both

Overview of attention for article published in New England Journal of Medicine, December 1998

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

policy: 2 policy sources
twitter: 2 X users

guideline: 15 clinical guideline sources

Readers on

mendeley: 27 Mendeley

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 60,348 followers.

@cleverwebber @ErinMcCreary @OncIDPharmd Largest prophylaxis study I'm aware of is this one, and it's 1500 mg once-daily. Might have been used to get the FDA indication. https://t.co/fRceXvc9uK

Atovaquone Compared with Dapsone for the Prevention of Pneumocystis carinii Pneumonia in Patients with HIV Infection Who Cannot Tolerate Trimethoprim, Sulfonamides, or Both | NEJM https://t.co/D7kCJNEfke

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.